- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2016
- Public Summary Document (PSD) March 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2016 PBAC Meeting - Word
Bevacizumab – March 2016
Bevacizumab: 100 mg/4 mL injection, 1 x 4 mL vial 400 mg/16 mL injection, 1 x 16 mL vial, Avastin®
Last updated
1 July 2016